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ABSTRACT
A stability-indicating high performance thin layer chromatographic (HPTLC) method for the densitometric analysis of nadifloxacin in microemulsions was developed and validated according to the guidelines of the International Conference on Harmonization (ICH). The compact spot for nadifloxacin was found at an R f value of 0.39 ± 0.02 at an absorption wavelength of 288 nm using a
mobile phase consisting of chloroform : methanol : formic acid (7.5 : 2.0 : 0.5 v/v). The linear regression data for the calibration plots
(r2 = 0.9981) was found with respect to peak area in the concentration range of 50 - 600 ng/spot. The limit of detection (LOD) and
limit of quantification (LOQ) were 9.4 and 20.5 ng respectively. The drug was subjected to acid and alkaline hydrolysis, oxidation,
photo degradation and dry heat treatment. The peaks of degradation products were well-resolved from the peak of the standard drug
with significantly different R f values. Statistical analysis revealed that the developed HPTLC method is reproducible, selective and
accurate for the determination of nadifloxacin in its formulations. The method can effectively separate the drug from its degradation
products and be used for stability-indicating assay.
Key words: high performance thin layer chromatography, method validation, nadifloxacin, stability-indicating assay method, fluoroquinolone

INTRODUCTION
Nadifloxacin, designated chemically as 9-fluoro6,7-dihydro-8(4-hydroxy-1-piperidyl)-5-methyl-1-oxo1H,5H-benzo-(ij)-quinolizine-2-carboxylic acid (OPC7251) (Figure 1), is a second generation broad spectrum
fluoroquinolone with improved activity against Grampositive and Gram-negative bacteria, including S. aureus,
P. acnes and S. epidermidis. The bactericidal action of
nadifloxacin is mediated by inhibiting the formation of
supercoiled DNA by DNA gyrase (topoisomerase II), an
enzyme responsible for bacterial DNA replication(1). It is
used for the treatment of bacterial skin infection and acne
vulgaris.
According to literature review, only HPLC method
has been reported for the determination of nadifloxacin in plasma (2) while no analytical method has been
* Author for correspondence. Tel: +00-91-9818529286;
Fax: +00-91-11-26059663; E-mail: s baboota@rediffmail.com;
sbaboota@jamiahamdard.ac.in

reported for the estimation of nadifloxacin in bulk drugs
and dosage forms which indicate stability. Based on the
stability indication method that is reported in the International Conference on Harmonization (ICH) guideline
Q1A (R2) titled “Stability testing of new drug substances
and products”, the stress testing of new drug substances
should be carried out to elucidate the inherent stability
characteristics of the active substances (3). Oxidation,
acid or base hydrolysis and photolytic degradation are
some of the required tests needed to evaluate degradation
O
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Figure 1. Chemical structure of nadifloxacin
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of active pharmaceutical ingredient (APIs). An ideal
stability indication method should quantify the drug per
se and also resolve its degradation products (4).
HPTLC is a powerful analytical technique because
of its reliability, simplicity, reproducibility and speed. It
is also an economical method that utilises relatively small
amounts of solvents and minimum sample clean-up. Most
importantly, a large number of samples can be quickly
and simultaneously analyzed. Unlike HPLC, HPTLC
has no limitation on the choice of mobile phase. Mobile
phases having pH 8 and above can be employed(5). It
also allows simultaneous assay of several compounds in
herbal extracts and formulations.
The main objective of the present work was to
develop an economical, specific, accurate, reproducible
and stability-indicating HPTLC densitometric method
for the estimation of nadifloxacin, in the presence of its
degradation products and related impurities, in microemulsion pharmaceutical dosage form and validate it
according to ICH guidelines.

MATERIALS AND METHODS
I. Materials
Nadifloxacin was received as a gift sample from
Wochardt Laboratory Limited (Aurangabad, India). Other
chemicals and reagents used were purchased from Merck
Limited (Mumbai, India) and were of analytical grade.
II. HPTLC Instrumentation
The sample was spotted with a band width of 6 mm
using a Camag microlitre syringe on pre-coated silica gel
aluminium plates 60F254 (20 cm × 10 cm with thickness
of 0.2 mm, E. Merck (Darmstadt, Germany). A sample
applicator, Linomat V (Camag, Muttenz, Switzerland)
was used. The slit dimension was kept at 6 mm × 0.45 mm
and a scanning speed of 20 mm/s was employed. A
constant application rate of 100 nL/s was used and the
band interval was 10 mm. For the application of sample
by spray-on technique, the required volume with an
additional 2.2 µL (internal storage volume) was filled in
the syringe. The mobile phase consisted of chloroform :
acetone : formic acid (7.5 : 2.0 : 0.5 v/v). Linear ascending
development was carried out in a 20 cm × 20 cm
twin-trough glass chamber saturated with the mobile
phase for up to 30 min at room temperature (25 ± 2°C)
and a relative humidity of 55 ± 5%. After the development, the TLC plates were dried in a current of air with
an air dryer. Densitometric scanning was performed on
Camag TLC Scanner III at an absorption wavelength of
288 nm. The source of radiation utilized was a deuterium
lamp emitting continuous UV spectrum in the range of
190-400 nm. Evaluation was performed using linear
regression analysis based on peak area.

III. Calibration of Nadifloxacin
A stock solution of nadifloxacin (100 µg/mL) was
prepared in methanol. 0.5, 1, 2, 4, 5 and 6 µL of the stock
solution was applied on a TLC plate to obtain concentrations of 50, 100, 200, 400, 500 and 600 ng/spot, respectively. Each concentration was spotted three times on the
TLC plate. A calibration curve was obtained by plotting
peak area against the corresponding concentration and
linear least-square regression analysis was performed.
IV. Method Validation
Precision, robustness, limit of detection (LOD),
limit of quantification (LOQ), recovery and ruggedness (6) of the developed HPTLC method was evaluated
according to the ICH guideline Q2 (R1). The procedure
used to study these parameters was the same as previously reported for other HPTLC methods (4,7).
(I) Precision
Precision validation was performed in two stages,
namely system repeatability and method repeatability.
For system repeatability, the repeatability of sample
application and measurement of peak areas were carried
out by analyzing six samples at two concentrations (200
and 300 ng/spot) on the same day. For method repeatability, intra and inter-day variations were studied for
three different concentration levels of nadifloxacin (100,
200 and 300 ng/spot).
(II) Limit of Detection (LOD) and Limit of Quantification
(LOQ)
In order to determine the detection and quantification limits, nadifloxacin drug concentrations in the lower
part of calibration curve were used. Nadifloxacin solutions of 50, 100, 200 and 300 ng/mL were prepared and
applied in triplicate. The amount of nadifloxacin concentration by spot versus average response (peak area) was
plotted. The equation of this curve was also determined
and an estimate of the target response (ybl), which corresponded to the intersection of the curve, was obtained.
Subsequently, a second curve was plotted with concentration versus standard deviation of the responses. From this
equation, an estimate of standard deviation of the target
(sbl), which corresponded to the intersection of curve,
was obtained. The limits of detection and quantification
were calculated using the following formulae:
Limit of Detection =

ybl + 3 sbl
b

Limit of Quantification =

ybl + 10 sbl
b

where b = slope of the curve
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(III) Recovery Studies
A stock solution of nadifloxacin was prepared. The
microemulsion formulation was first analyzed by the
proposed method. The analyzed samples were spiked
with 50%, 100% and 150% of the standard drug and
the mixture was re-analyzed. The experiment for each
recovery sample was carried out six times to check the
recovery of the drug at different formulation levels.
(IV) Robustness
Robustness of the developed method was determined by introducing small changes in the mobile phase
composition and the effect on the result was examined.
Mobile phases comsisting of different compositions
of chloroform and acetone with the same formic acid
concentration (7.8 : 1.7 : 0.5 v/v and 7.2 : 2.3 : 0.5 v/v )
were used. The temperature and relative humidity varied
in the range of ± 5%. The plates were pre-washed with
methanol and activated at 60 ± 5°C for 2, 5 and 7 min
prior to use. The time from spotting to chromatographic
analysis and from chromatographic analysis to scanning was varied by 0, 20, 40 and 60 min. Robustness of
the method was evaluated at two different concentration
levels of 200 and 400 ng/spot.
(V) Ruggedness
For ruggedness, a solution of 400 ng/spot of nadifloxacin was prepared and analyzed at 0, 6, 12, 24, 48 and
72 h.
V. Analysis of Nadifloxacin in Microemulsion
To determine the content of nadifloxacin in microemulsion, 1 mL of microemulsion (which contains 1 mg
of nadifloxacin) was diluted with methanol and the final
solution was diluted to obtain 100 µg/mL of nadifloxacin.
Two micromilliliter (200 ng/spot) of the solution was
applied on the TLC plate, followed by development and
scanning as described in Materials and Methods Section
II. The analysis was carried out in triplicate. The possibility of interference by excipients was observed.
VI. Stress Degradation Study of Nadifloxacin
For the stress degradation study of nadifloxacin, the
samples were separately treated with acid, base, dry heat,
day light, UV light and H 2O2. The chromatograms were
developed.
(I) Acid- and Base-Induced Degradation
Ten milligram of nadifloxacin was dissolved in 10
mL of methanol. One milliliter of the solution was used
and the volume was made up to 10 mL with 0.1 N HCl

and 0.1 N NaOH separately. The solutions yielded
extreme pH values of 1 and 13, respectively. These solutions were kept for 3 days at 50°C in a dark place in order
to exclude the possible effect of light. The resultant solutions were applied on TLC plates in triplicate (5 µL each,
i.e. 500 ng/spot).
(II) Hydrogen Peroxide-Induced Degradation
Ten milligram of nadifloxacin was dissolved in 10 mL
of methanol. 1 mL of solution was used and the volume
was made up to 10 mL with 30% v/v H 2O2 and refluxed.
The solutions were kept for 3 days at room temperature in
a dark place in order to exclude the possible effect of light.
The resultant solutions were applied on TLC plates in triplicate (5 µL each, i.e. 500 ng/spot).
(III) Photo-Stability
The photo-stability test was performed in the presence of UV light (254 nm) and daylight. The methanolic
solution having a concentration of 100 µg/mL was kept
for 3 days in UV light and for 7 days in daylight. The
resultant solution was applied on TLC plates in triplicate
(5 µL each, i.e. 500 ng/spot).
(IV) Dry Heat Degradation
The dry heat degradation study was performed using
a high precision hot air oven (Narang Scientific Works,
New Delhi, India) capable of controlling the temperature
within ± 2ºC The methanolic solution having a concentration of 100 µg/mL was kept for 8 h in an oven to expose
it to dry heat (100ºC). The resultant solution was applied
on TLC plates in triplicate (5 µL each, i.e. 500 ng/spot).

RESULTS AND DISCUSSION
I. Optimization of Mobile Phase
The TLC procedure was optimized with a view to
develop a stability-indicating assay method to quantify
nadifloxacin in microemulsion formulations. Chloroform was selected as one of the components of the mobile
phase with acceptable resolution. However, the R f value
was too low, so the solvent strength was increased by
adding polar solvents. Acetone was added to chloroform
in ratios of 3 : 7, 2 : 8, 1.5 : 8.5, 2.5 : 7.5 and 0.5 : 9.5 and
the chromatograms were developed. The mobile phase
comprising of chloroform : acetone (7.5 : 2.5 v/v) showed
good resolution with R f = 0.39 for nadifloxacin but tailing
was observed and the spot of nadifloxacin was slightly
diffused. Addition of formic acid improved the characteristics of the spot and its optimum quantity was 0.5 mL.
The final mobile phase selected was a mixture of chloroform : acetone : formic acid (7.5 : 2 : 0.5 v/v), which
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respectively. This indicated that the system performance
was very good and suitable for nadifloxacin analysis. The
measurement of peak area at three different concentration levels (100, 200 and 300 ng/spot) showed low values
of S.E. and % RSD for inter and intra-day variations,
suggesting that the method had excellent precision.

gave a well-defined symmetrical peak of nadifloxacin at
R f = 0.39 ± 0.02 (Figure 2). Well-defined spots were
obtained when the chamber was saturated with mobile
phase for 0.5 h at room temperature.
II. Calibration Curve

(II) Limit of Detection (LOD) and Limit of Quantification
(LOQ)

The linear regression data for the calibration curves
(n = 3) shown in Table 1 indicated a good linear relationship in the concentration range of 50 - 600 ng/spot with
respect to the peak area and height. No significant difference was observed in the slopes of the standard curves
(ANOVA, p < 0.05).

The calibration curve of analyte versus average
response (peak area) was plotted. The regression equation was obtained (y = 15.021x + 68.78) with a regression
coefficient of 0.9972. The limit of detection and limit of
quantification were determined by the method described
in Materials and Methods Section IV-II. From the graphs
obtained between concentration and average response,
and between concentration and standard deviation, the
ybl and sbl values were found to be 68.78 and 23.91,
respectively. Therefore, the limit of detection was found
to be 9.4 ng and the limit of quantification was found to

III. Method Validation
(I) Precision
The repeatability of sample application and peak
areas measured were expressed in terms of % RSD and
the results revealed good system repeatability, intra
and inter-day precision (Table 2 and 3). The % RSD for
system repeatability of sample application (200 and
300 ng/spot) was measured and found to be 0.12 and 0.10,

Table 1. Linear regression data for the calibration curves (n = 3)
Parameters

AU

400
350

With Respect to the Mean Area

Linearity range

50 - 600

Correlation coefficient

0.9981
16.293 ± 0.08

Slope ± S.D.
a

Confidence limit of slope

nadifloxacin

300

16.05 - 16.45

b

Intercept ± S.D.

250

134.77 ± 1.39
a

Confidence limit of Intercept
200

a
b

150
100

95% confidence limit
Percentage bias of intercept = -0.013

Table 2. System repeatability data for precision study of the HPTLC
method (n = 6)

50
0
0.00

131.42 - 137.86

0.10 0.20

0.30

0.40

0.50 0.60

0.70 0.80

0.90

Rf

Figure 2. A typical HPTLC chromatogram of standard nadifloxacin
(400 ng/spot, R f = 0.39). The mobile phase consisted of chloroform :
methanol : formic acid (7.5 : 2.0 : 0.5 v/v).

Amount
(ng/spot)

Mean
Area

SD

RSD (%)

Standard
Error

200

3272.35

3.61

0.12

2.08

300

4491.00

4.51

0.10

2.60

Table 3. Intra and inter-day precision data of the HPTLC method (n = 6)
Intra-day precision

Inter-day precision

Amount
(ng/spot)

Mean Area

S.D.

RSD (%)

S.E.

Mean Area

S.D.

RSD (%)

S.E.

100

1194.47

2.83

0.24

1.64

1322.87

3.18

0.24

1.84

200

3436.72

3.06

0.09

1.83

3297.81

3.29

0.10

1.90

300

4535.46

2.84

0.06

1.64

4528.00

4.58

0.10

2.65
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be 20.5 ng, indicating that the method was adequately
sensitive.
(III) Recovery Studies
The proposed method was used for extraction and
subsequent estimation of nadifloxacin from the microemulsion formulation after spiking known amounts of the
drug (50, 100 and 150%) into the formulation. Accuracy
was determined based on the amount of drug recovered.
The results were shown in Table 4 and it was concluded
that the present method was accurate for the estimation
of nadifloxacin in pharmaceutical dosage forms, especially microemulsions.

IV. Analysis of Nadifloxacin in Microemulsion Formulation
When the formulation was analysed, three spots
at R f 0.18, 0.39 and 0.64 (Figure 3) were observed in
the chromatogram. The other spots might belong to the
excipients present in the formulation. The drug content
was found to be 99.5% with RSD and S.E. of 0.15% and

300

AU
250

(IV) Robustness

200

The low values of RSD and S.E. obtained after
introducing a small change in mobile phase composition indicated robustness of the method (Table 5). There
was no significant variation in the slope values (ANOVA,
p < 0.05).

150

100

50

(V) Ruggedness
A low RSD value of 0.09% from the peak areas
obtained by analyzing the same drug solution at a
concentration of 400 ng/spot after 0, 6, 12, 24, 48 and
72 h showed ruggedness of the method.

nadifloxacin

0
0.00

3

1

0.20

0.40

0.60

0.80

1.00

Table 4. Recovery studiesa (n = 6)
Excess Drug Added
to Analyte (%)

Theoretical Amount
(ng)

Amount Recovered
(ng)

Recovery
(%)

RSD
(%)

S.E.

0

100

99.2

99.2

0.80

1.36

50

150

148.6

99.1

0.89

1.63

100

200

199.0

99.5

0.70

1.71

150

250

249.8

99.9

0.31

1.73

Table 5. Robustness of the method (n = 3)
Parameters

Rf

Figure 3. Chromatogram of nadif loxacin and the excipients in
microemulsion formulation

S.D. of Peak Area

RSD (%)

S.E.

Rf Value ± S.D.

Mobile phase composition

1.34

0.12

0.37

0.39 ± 0.07

Volume of mobile phase

1.13

0.10

0.41

0.39 ± 0.06

Temperature

1.11

0.08

0.29

0.39 ± 0.05

Relative humidity

0.94

0.08

0.27

0.39 ± 0.06

Plate pre-treatment

0.89

0.07

0.25

0.39 ± 0.06

Time from spotting to chromatographic analysis

0.59

0.05

0.17

0.39 ± 0.04

Time from chromatographic analysis to scanning

0.47

0.03

0.16

0.39 ± 0.05
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Table 6. Stress degradation study of nadifloxacin (n = 3)
No.

Sample Exposure Condition

Time
(Days)

Rf Value of
Degradation Products

Nadifloxacin Remaining
± S.D. (n = 3, 500 ng/spot)

S.E.

Recovery
(%)

1

Acid, 0.1N HCl (50°C)

3

0.64, 0.68, 0.71

161.02 ± 1.74

1.26

32.6

2

Base, 0.1N NaOH (50°C)

3

0.19, 0.42, 0.47, 0.50

388.44 ± 1.89

1.32

77.7

3

H2O2, 30% v/v (25°C)

3

0.06, 0.43, 0.51, 0.64

407.50 ± 3.2

1.57

81.5

4

Dry heat (100°C)

8h

0.42, 0.48, 0.53

356.33 ± 2.83

1.44

71.6

5

Photostability - Daylight

7

0.06, 0.54, 0.58

372.61 ± 4.12

1.64

74.5

6

Photostability - UV light (254 nm)

3

0.03, 0.27, 0.49, 0.63

295.53 ± 2.83

1.38

59.1

300

AU

600

Base, 0.1N NaOH, 50°C

AU

Acid, 0.1N HCl, 50°C

500

250

400
200

nadifloxacin
300

150

200
nadifloxacin
100

100

50

0
0.00

0
0.00

4 5

1

2

0.10

0.20

0.30

0.40

0.50

0.60

34

0.70

0.80

0.90

Rf

Figure 5. HPTLC chromatogram of acid-degraded products of
nadifloxacin
0.10 0.20

0.30

0.40

0.50 0.60

0.70 0.80

0.90

Rf

Figure 4. HPTLC chromatogram of base-degraded products of
nadifloxacin

1.79, respectively. The results suggested that degradation
of nadifloxacin had not occurred in the formulation when
analyzed by this method and excipients did not affect
the determination of the drug in the formulation. The
low RSD value supported the suitability of this method
for routine analysis of nadifloxacin in the novel drug
delivery system.
V. Stress Degradation Study of Nadifloxacin
The chromatogram of the samples degraded by acid,
base, hydrogen peroxide, dry heat, UV light and day light
showed well-separated spots of nadifloxacin, as well as
some additional peaks at different R f values (Table 6).
(I) Acid- and Base-Induced Degradation
It was found that the acid and base-treated samples
showed different degradation products at different R f
values. The base degradation products were found at
R f 0.19, 0.42, 0.47 and 0.50 (Figure 4). The area of the

base degradation product at R f 0.47 was found to be
more significant, compared to the other three degradation products. The recovery of nadifloxacin in the basetreated sample was found to be 77.7%.
The acid-treated drug sample showed three degradation products at R f 0.64, 0.68 and 0.71 (Figure 5). The
spots of degradation products were well-resolved from
the drug spot. The recovery of nadifloxacin in the acidtreated sample was found to be 32.6%. From the recovery
study, more degradation of nadifloxacin was observed in
the acidic medium, compared to the basic medium.
(II) Hydrogen Peroxide-Induced Degradation
The chromatogram of the sample treated with
30% v/v H 2O2 showed four additional peaks at R f 0.06,
0.43, 0.51 and 0.64 (Figure 6). The recovery of nadifloxacin in the H 2O2-treated sample was found to be 81.5%.
(III) Photo-Stability
When the chromatogram was developed and evaluated, it showed a well-separated spot of pure nadifloxacin
as well as some additional peaks of different R f values.
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The additional peaks of different R f values 0.03, 0.27,
0.49 and 0.63 (Figure 7) and 0.06, 0.54, 0.58 (Figure 8)
might belong to degraded products of nadifloxacin which
were well-resolved from the pure drug in UV light and
day light respectively. The recovery of drug was found to
be 59.1% in UV light and 74.5% in day light. From the
recovery study, the drug showed significant degradation
in UV light and day light.

products of the drug. The recovery of the drug was found
to be 71.3%.
From the stress degradation study of nadifloxacin, it
was observed that the drug showed maximum degradation in acidic medium and UV light.

(IV) Dry Heat Degradation

The introduction of HPTLC estimation in pharmaceutical analysis represents a major step in terms of
quality assurance. The developed HPTLC method is
precise, accurate, specific and stable. Statistical analysis
indicated that the method is repeatable and selective for

The chromatogram of the dry heat-treated sample
showed three additional peaks at R f values of 0.43, 0.49
and 0.53 (Figure 9) which might belong to the degraded

AU

400

H2O2 (30% v/v), 25°C

CONCLUSIONS

AU

350

300

UV light, 254nm

250

nadifloxacin

300

200

250

nadifloxacin

200

150

150

100

100
50

1

0
0.00 0.10

0.20

0.30

5

3

4

0.40

0.50

0.60

50

0.70

0.80

0.90

400

AU

0
0.00 0.10

Rf

Figure 6. HPTLC chromatogram of H 2 O 2 -degraded products of
nadifloxacin

AU

350

0.20

5

4

0.30

0.40

0.50

0.60

0.70

0.80

0.90

Rf

Figure 7. HPTLC chromatogram of UV light-degraded products of
nadifloxacin

300

Day light

2

Dry heat, 100°C

250

nadifloxacin
300

200

250
200

nadifloxacin

150

150

100

100
50

1

0
0.00

50

3 4

0.20

0.40

0.60

0.80

1.00

Rf

Figure 8. HPTLC chromatogram of day light-degraded products of
nadifloxacin

0
0.00

2 3 4

0.20

0.40

0.60

0.80

1.00

Rf

Figure 9. HPTLC chromatogram of dry heat-degraded products of
nadifloxacin
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the analysis of nadifloxacin in pharmaceutical formulations with no interference from excipients. The method
can be used to determine the purity of drug available from
various sources by analyzing it for related substances
and impurities. This method is proposed for the analysis
of nadifloxacin and its degradation products in stability
samples in industries. It may be further extended for
quantitative estimation of nadifloxacin in plasma and
other biological fluids. As the method is capable of separating the drug from its degradation products, it can be
employed as a stability-indicating assay method.
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